Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.

@article{Everett2018ChronicGD,
  title={Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.},
  author={Ashlyn S Everett and Peter G. Pavlidakey and Carlo M. Contreras and Jennifer F De Los Santos and Ju Young Kim and Svetlana B. McKee and Howard L. Kaufman and Robert M Conry},
  journal={Journal of cutaneous pathology},
  year={2018},
  volume={45 1},
  pages={
          48-53
        }
}
Talimogene laherparepvec (TVEC) is the first oncolytic viral immunotherapy approved by the FDA, for advanced melanoma consisting of genetically modified herpes simplex type 1 virus which selectively replicates causing tumor lysis, expressing granulocyte macrophage-colony stimulating factor (GM-CSF) and activating dendritic cells. Intratumoral injection of TVEC produces objective response in 41% of stage IIB-IV M1a melanoma. However, clinical response assessment can be problematic due to immune… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS